Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing a strong performance, driven by the rise of the National Index for Hong Kong Innovative Drugs, with leading stocks such as BeiGene, InnoCare Pharma, and 3SBio showing significant gains [1] Group 1: Market Performance - The Hong Kong Innovative Drug ETF (159567) opened higher and rose over 3% by 9:50 AM, with a trading volume exceeding 600 million yuan, indicating a slight increase compared to the previous day [1] - The strong performance of the index has positively influenced the trading activity of popular ETFs in the market [1] Group 2: Investment Outlook - CITIC Securities released a report forecasting the investment trends in the pharmaceutical sector through 2026, highlighting the concentration of innovation among Chinese pharmaceutical companies and supportive policies for innovative drugs and medical devices [1] - The healthcare industry is expected to gradually return to a market pricing system driven by clinical value and demand, leading to a stable and sustainable domestic pharmaceutical market environment [1] - Listed companies in the sector are anticipated to experience continuous and stable earnings growth, contributing to a positive growth outlook for the industry [1] Group 3: Investment Opportunities - The Hong Kong Innovative Drug ETF (159567) tracks the National Index for Hong Kong Innovative Drugs, aiming to reflect the operational characteristics of listed companies in the innovative drug sector within the Hong Kong Stock Connect [1] - Investors can also access the Hong Kong Innovative Drug ETF through connecting funds, providing an opportunity to capitalize on the upward potential of the innovative drug sector [1]